- $491.46m
- $389.93m
- $56.20m
908 Devices Q2 revenue beats on increased VipIR sales
908 Devices Inc. expected to post a loss of 17 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber
908 Devices' Q1 revenue beats expectations
U.S. STOCKS ON THE MOVE-AMD, Apollo, Deckers Outdoor
Brief: 908 Devices Q1 Revenue USD 13.4 Million Vs. IBES Estimate USD 13.2 Million
908 Devices rises as it buys Swiss drug detection firm NIRLAB
Brief: 908 Devices Files For Mixed Shelf Offering Of Up To $100 Million
908 Devices Q4 revenue beats on FTIR product strength
Brief: 908 Devices Q4 Operating Expenses USD 6.1 Million
Brief: 908 Devices Announces Strong Preliminary Financial Results For Fourth Quarter And Full Year 2025
Handheld analyzer maker 908 Devices Inc's Q3 revenue beats estimates
Brief: 908 Devices Q3 Net Income USD -15 Million
908 Devices Inc reports results for the quarter ended June 30 - Earnings Summary
Chemical analysis tools maker 908 Devices Q2 revenue beats estimates, raises FY forecast
Brief: 908 Devices Appoints Dr. Brandi Vann, Former U.S. Principal Deputy Assistant Secretary For Nuclear, Chemical, And Biological Defense, To Its Board Of Directors
908 Devices Inc expected to post a loss of 18 cents a share - Earnings Preview